Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events

This publication has 41 references indexed in Scilit:

• Physicians’ interpretation of “class effects”
  Journal of the American College of Cardiology, 2002
• The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?
  Current Opinion in Nephrology and Hypertension, 2001
• The HOPE study: Comparison with other trials of secondary prevention
  Published by Oxford University Press (OUP) ,2001
• Kosten des Typ-2-Diabetes in Deutschland
  Deutsche Medizinische Wochenschrift (1946), 2001
• Cost effectiveness of ramipril treatment for cardiovascular risk reduction
  Heart, 2001
• Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events
  Journal of Medical Economics, 2000
• Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
  European Heart Journal, 1998
• The Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in Germany
  PharmacoEconomics, 1998
• Kosten-Wirksamkeits-Analyse der Reinfarktprophylaxe mit niedrig dosierter Acetylsalicylsäure: Modellrechnung
  International Journal of Public Health, 1997
• Discounting of Health Benefits in the Pharmacoeconomic Analysis of Drug Therapies
  PharmacoEconomics, 1992